223 related articles for article (PubMed ID: 20460432)
1. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression.
Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
Mol Pharmacol; 2010 Aug; 78(2):310-8. PubMed ID: 20460432
[TBL] [Abstract][Full Text] [Related]
2. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
3. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
Natarajan K; Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
PLoS One; 2013; 8(9):e74653. PubMed ID: 24040307
[TBL] [Abstract][Full Text] [Related]
4. Pim-1L Protects Cell Surface-Resident ABCA1 From Lysosomal Degradation in Hepatocytes and Thereby Regulates Plasma High-Density Lipoprotein Level.
Katsube A; Hayashi H; Kusuhara H
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2304-2314. PubMed ID: 27765770
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Skp2 levels by the Pim-1 protein kinase.
Cen B; Mahajan S; Zemskova M; Beharry Z; Lin YW; Cramer SD; Lilly MB; Kraft AS
J Biol Chem; 2010 Sep; 285(38):29128-37. PubMed ID: 20663873
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.
Shukla S; Skoumbourdis AP; Walsh MJ; Hartz AM; Fung KL; Wu CP; Gottesman MM; Bauer B; Thomas CJ; Ambudkar SV
Mol Pharm; 2011 Aug; 8(4):1292-302. PubMed ID: 21630681
[TBL] [Abstract][Full Text] [Related]
7. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.
Xie Y; Xu K; Linn DE; Yang X; Guo Z; Shimelis H; Nakanishi T; Ross DD; Chen H; Fazli L; Gleave ME; Qiu Y
J Biol Chem; 2008 Feb; 283(6):3349-3356. PubMed ID: 18056989
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
9. Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.
Shukla S; Schwartz C; Kapoor K; Kouanda A; Ambudkar SV
Drug Metab Dispos; 2012 Feb; 40(2):304-12. PubMed ID: 22041108
[TBL] [Abstract][Full Text] [Related]
10. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.
Ye S; MacEachran DP; Hamilton JW; O'Toole GA; Stanton BA
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C807-18. PubMed ID: 18650266
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Robey RW; Shukla S; Finley EM; Oldham RK; Barnett D; Ambudkar SV; Fojo T; Bates SE
Biochem Pharmacol; 2008 Mar; 75(6):1302-12. PubMed ID: 18234154
[TBL] [Abstract][Full Text] [Related]
12. FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin--proteasome pathway in cancer cells.
Katayama K; Noguchi K; Sugimoto Y
Cancer Sci; 2013 Jun; 104(6):694-702. PubMed ID: 23465077
[TBL] [Abstract][Full Text] [Related]
13. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.
Walter RB; Pirga JL; Cronk MR; Mayer S; Appelbaum FR; Banker DE
Blood; 2005 Nov; 106(10):3584-93. PubMed ID: 16051742
[TBL] [Abstract][Full Text] [Related]
14. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
15. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.
Xie Y; Xu K; Dai B; Guo Z; Jiang T; Chen H; Qiu Y
Oncogene; 2006 Jan; 25(1):70-8. PubMed ID: 16186805
[TBL] [Abstract][Full Text] [Related]
16. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
[TBL] [Abstract][Full Text] [Related]
18. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
19. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
Oncologist; 2012; 17(4):512. PubMed ID: 22416063
[TBL] [Abstract][Full Text] [Related]
20. Dual regulation of P-glycoprotein expression by trichostatin A in cancer cell lines.
Balaguer TM; Gómez-Martínez A; García-Morales P; Lacueva J; Calpena R; Reverte LR; Riquelme NL; Martinez-Lacaci I; Ferragut JA; Saceda M
BMC Mol Biol; 2012 Jul; 13():25. PubMed ID: 22846052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
